Emergent BioSolutions’ Emergard has been selected by the U.S. Department of Defense (DoD) and Battelle to be tested against and developed to U.S. military specifications as a platform for nerve agent antidote delivery. Emergard is a rugged, military-grade auto-injector platform designed to be transported, stored, and operated in a military environment and to ensure needle penetration and successful injection through chemical protective gear. Development and testing of Emergard is expected to be ...